Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Link between Abdominal Obesity Indices and the Progression of Liver Fibrosis, Insights from a Population-Based Study

  • Julián, María Teresa|||0000-0003-2524-1823
  • Arteaga, Ingrid
  • Torán-Monserrat, Pere|||0000-0002-9865-7427
  • Pera, Guillem|||0000-0003-3188-7268
  • Pérez-Montes de Oca, Alejandra|||0000-0001-8807-1935
  • Ruiz-Rojano, Irene
  • Casademunt-Gras, Elena
  • Chacón, Carla|||0000-0001-8524-6189
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
There is currently no available information on the correlation between abdominal obesity indices and the risk of liver fibrosis progression. We aimed to investigate the relationship between the body mass index (BMI), waist circumference (WC), and the visceral adiposity index (VAI) with the progression of liver fibrosis. The study also evaluated the association between these indices and the prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) and liver fibrosis. A total of 1403 subjects participated in the cross-sectional and longitudinal population-based study. Liver stiffness was assessed via transient elastography, at baseline and follow-up (median: 4.2 years). The subgroup with dysglycemia was also analyzed. In the cross-sectional study, the highest quartile of VAI, BMI ≥ 30 kg/m 2, and abdominal obesity showed significant associations with the prevalence of MASLD and liver fibrosis, as well as with fibrosis progression. However, VAI showed no association with MASLD incidence. Among the dysglycemic subjects, there was no observed association between VAI and the incidence of MASLD or the progression of fibrosis. In conclusion, the BMI, WC, and the VAI are associated with an increased risk of progression to moderate-to-advanced liver fibrosis in the general population. However, the VAI does not perform better than the BMI and WC measurement.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Use of Rifaximin in Patients With Cirrhosis

  • Caraceni, Paolo|||0000-0002-1439-056X
  • Vargas Blasco, Víctor|||0000-0002-7190-6948
  • Solà, Elsa|||0000-0001-6897-2760
  • Alessandria, Carlo|||0000-0001-5468-694X
  • de Wit, Koos|||0000-0001-8472-8549
  • Trebicka, Jonel|||0000-0002-7028-3881
  • Angeli, Paolo|||0000-0002-1913-0716
  • Mookerjee, Rajeshwar P.
  • Durand, François
  • Pose, Elisa|||0000-0002-0224-7686
  • Krag, Aleksander|||0000-0002-9598-4932
  • Bajaj, Jasmohan S.|||0000-0003-4928-3681
  • Beuers, Ulrich
  • Ginès, Pere|||0000-0003-4657-4504
Rifaximin is an oral nonsystemic antibiotic with minimal gastrointestinal absorption and broad-spectrum antibacterial activity covering both gram-positive and gram-negative organisms. Rifaximin is currently used worldwide in patients with cirrhosis for preventing recurrent HE because its efficacy and safety have been proven by large randomized clinical trials. In the last decade, experimental and clinical evidence suggest that rifaximin could have other beneficial effects on the course of cirrhosis by modulating the gut microbiome and affecting the gut-liver axis, which in turn can interfere with major events of the pathophysiological cascade underlying decompensated cirrhosis, such as systemic inflammatory syndrome, portal hypertension, and bacterial infections. However, the use of rifaximin for prevention or treatment of other complications, including spontaneous bacterial peritonitis or other bacterial infections, is not accepted because evidence by clinical trials is still very weak. The present review deals in the first part with the potential impact of rifaximin on pathogenic mechanisms in liver diseases, whereas in the second part, its clinical effects are critically discussed. It clearly emerges that, because of its potential activity on multiple pathogenic events, the efficacy of rifaximin in the prevention or management of complications other than HE deserves to be investigated extensively. The results of double-blinded, adequately powered randomized clinical trials assessing the effect of rifaximin, alone or in combination with other drugs, on hard clinical endpoints, such as decompensation of cirrhosis, acute-on-chronic liver failure, and mortality, are therefore eagerly awaited.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Abdominal obesity and dsyglycemia are risk factors for liver fibrosis progression in NAFLD subjects, A population-based study

  • Julián, María Teresa|||0000-0003-2524-1823
  • Ballesta Purroy, Sílvia|||0000-0001-8057-1804
  • Pera, Guillem|||0000-0003-3188-7268
  • Pérez-Montes de Oca, Alejandra|||0000-0001-8807-1935
  • Soldevila i Madorell, Berta|||0000-0002-4582-4201
  • Caballería, Llorenç|||0000-0002-7990-0719
  • Morillas Cunill, Rosa Ma|||0000-0001-9117-5049
  • Expósito, Carmen|||0000-0002-9246-3779
  • Martinez Escude, Alba|||0000-0003-0667-1609
  • Puig Domingo, Manuel|||0000-0002-6744-7195
  • Franch-Nadal, Josep|||0000-0002-5175-1555
  • Torán, Pere
  • Cusi, Kenneth|||0000-0002-8629-418X
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Mauricio, Didac|||0000-0002-2868-0250
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
To investigate longitudinal changes in the liver stiffness measurement (LSM) in the general adult population without known liver disease and to describe its association with metabolic risk factors, with a special focus on subjects with non-alcoholic fatty liver disease (NAFLD) and dysglycemia. A longitudinal adult population-based cohort study was conducted in Catalonia. LSM was measured by transient elastography (TE) at baseline and follow-up (median: 4.2 years). Subgroup with NAFLD and dysglycemia were analyzed. Moderate-to-advanced liver fibrosis was defined as LSM ≥8.0 kPa and LSM ≥9.2 kPa respectively. Among 1.478 subjects evaluated, the cumulative incidence of LSM ≥8.0 kPa and ≥9.2 kPa at follow-up was 2.8% and 1.9%, respectively. This incidence was higher in NAFLD (7.1% for LSM ≥8.0 kPa and 5% for LSM ≥9.2 kPa) and dysglycemia (6.2% for LSM ≥8.0 kPa and 4.7% for LSM ≥9.2 kPa) subgroups. In the global cohort, the multivariate analyses showed that dysglycemia, abdominal obesity and atherogenic dyslipidemia were significantly associated with progression to moderate-to-advanced liver fibrosis. Female sex was negatively associated. In subjects with NAFLD, abdominal obesity and dysglycemia were associated with changes in LSM to ≥8.0 kPa and ≥9.2 kPa at follow-up. A decline in LSM value to <8 kPa was observed in 64% of those subjects with a baseline LSM ≥8.0 kPa. In this population study, the presence of abdominal obesity and dysglycemia were the main risk metabolic factors associated with moderate-to-advanced liver fibrosis development over time in general populations as well as in subjects with NAFLD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Dysglycemia in young women attenuates the protective effect against fatty liver disease

  • Pérez-Montes de Oca, Alejandra|||0000-0001-8807-1935
  • Julián, María Teresa|||0000-0003-2524-1823
  • Pera, Guillem|||0000-0003-3188-7268
  • Caballería, Llorenç|||0000-0002-7990-0719
  • Morillas Cunill, Rosa Ma|||0000-0001-9117-5049
  • Torán-Monserrat, Pere|||0000-0002-9865-7427
  • Expósito, Carmen|||0000-0002-9246-3779
  • Franch-Nadal, Josep|||0000-0002-5175-1555
  • Mauricio, Didac|||0000-0002-2868-0250
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
Sexual dimorphism has been reported in non-alcoholic fatty liver disease (NAFLD), similar to the sex differences evident with cardiovascular disease. Type 2 diabetes mellitus (T2D) significantly increases the risk and severity of NAFLD, but there is scarce information on whether T2D or altered glucose metabolism can modify the prevalence of NAFLD in men and women of reproductive age. To investigate the relationship between age, sex and NAFLD in subjects with and without dysglycemia. We analyzed 2,790 patients. NAFLD was characterized using established diagnostic criteria: one or more positive results on the fatty liver index and hepatic ultrasound. Liver fibrosis (liver stiffness measurement [LSM] ≥8.0 kPa) was assessed by Fibroscan ®. For analysis purposes, we included both T2D and prediabetes under the predefined condition of dysglycemia. The global prevalence of NAFLD was higher in men than in women (50% and 34%; P<0.001), and the prevalence increased with age in both sexes. Older women (≥ 50 years) had a higher prevalence than younger women (<50 years), both in the overall cohort and in non-dysglycemic subjects. In dysglycemic subjects, the prevalence of NAFLD was slightly higher in men (68% vs 61%, p=0.021); in younger subjects, there were no differences in the prevalence of NAFLD between men and women (68% vs 64%, respectively; p=0.635). We found an interaction between dysglycemia and female sex (odds ratio [OR] 1.6 95% confidence interval [CI] 1.0-2.4, p=0.030), and between and age ≥50 years (OR 0.6, 95% CI 0.3-1.0, p=0.046). The global prevalence of LSM ≥8.0 kPa was higher in men compared with women (8% vs 4%; p< 0.001). This prevalence increased with age, mainly in men. We did not find any association between liver fibrosis and age and gender. While the global prevalence of NAFLD is higher in men than in women across all ages, younger women with dysglycemia have a similar risk of developing NAFLD as men of a similar age. Therefore, the presence of dysglycemia may erase the protective effect of female sex against fatty liver disease.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Adipocyte fatty-acid binding protein is overexpressed in cirrhosis and correlates with clinical outcomes

  • Graupera, Isabel|||0000-0001-9170-9784
  • Coll, Mar|||0000-0003-3726-0087
  • Pose, Elisa|||0000-0002-0224-7686
  • Elia, Chiara
  • Piano, Salvatore|||0000-0002-9356-5830
  • Solà, Elsa|||0000-0001-6897-2760
  • Blaya, Delia
  • Huelin, Patricia
  • Solé Martí, Cristina|||0000-0002-6104-8345
  • Moreira, Rebeca
  • De Prada, Gloria
  • Fabrellas, Núria|||0000-0001-6720-0291
  • Juanola, Adrià|||0000-0003-4832-5130
  • Morales Ruiz, Manuel|||0000-0002-9074-2272
  • Sancho-Bru, Pau|||0000-0001-5569-9259
  • Villanueva, Càndid|||0000-0002-3674-914X
  • Ginès, Pere|||0000-0003-4657-4504
Fatty-acid-binding proteins (FABPs) are small intracellular proteins that coordinate lipid-mediated processes by targeting metabolic and immune response pathways. The aim of the study was to investigate plasma FABPs levels and their relationship with clinical outcomes in cirrhosis. Plasma levels of L-FABP1(liver and kidney), I-FABP2(intestine), and A-FABP4(adipocyte and macrophages) were measured in 274 patients with decompensated cirrhosis. Hepatic gene expression of FABPs was assessed in liver biopsies from patients with decompensated cirrhosis and in liver cell types from mice with cirrhosis. Immunohistochemistry of A-FABP4 in human liver biopsy was also performed. Plasma levels of FABPs were increased in patients with decompensated cirrhosis compared to those of healthy subjects (L-FABP1: 25 (17-39) vs 10 (9-17) ng/mL p = 0.001, I-FABP2: 1.1 (0.5-2.1) vs 0.6 (0.4-1) ng/mL p = 0.04 and A-FABP4: 37 (20-68) vs 16 (11-33) ng/mL p = 0.002), respectively. Increased A-FABP4 levels were associated with complications of cirrhosis, acute-on-chronic liver failure and poor survival. Hepatic A-FABP4 gene expression was upregulated in decompensated cirrhosis. Macrophages were the main liver cell that over-expressed A-FABP4 in experimental cirrhosis and increased A-FABP4 was found in macrophages of human biopsies by immunohistochemistry. A-FABP4 levels are increased in decompensated cirrhosis and correlate with poor outcomes. Liver macrophages appear to be the main source of A-FABP4 in decompensated cirrhosis.